ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents

Lilach Steiner, Galia Blum, Yael Friedmann, Alexander Levitzki*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The insulin-like growth factor-1 receptor (IGF-1 receptor) is a receptor tyrosine kinase, highly homologous to the insulin receptor. In contrast to the insulin receptor, which is mostly involved in metabolic pathways, the IGF-1 system plays a pivotal role in normal and neoplastic cell growth through anti-apoptotic, proliferative and metastatic pathways. Furthermore, IGF-1 receptor over-activation is found to correlate with a variety of tumors, such as breast cancer, prostate cancer, hematological malignancies, colorectal cancer and other proliferative diseases, such as psoriasis and papilloma. In addition, accumulating evidence implies that blockade of IGF-1 receptor activity causes reversal of tumor progression in cell lines as well as in animal tumor models. Because of the central role the IGF-1 receptor plays in oncogenic maintenance and metastatic processes, it is a highly appropriate target for anti-cancer agents. Here we report on a novel substrate-mimic family of IGF-1 receptor inhibitors. These compounds are tertiary aromatic amines, non-competitive with ATP and possess high affinity towards the IGF-1 receptor. The most potent compound, SBL02 inhibited the IGF-1 receptor with an IC50 of 170 nM in a cell-free kinase assay and was found to inhibit IGF-1 receptor auto-phosphorylation and substrate phosphorylation at the low micromolar range in cellular assays. SBL02 also blocks the formation of colonies in soft agar by cancer cells and inhibits the growth of keratinocytes and of HPV16 immortalized keratinocytes. This new family of non-ATP competitive, IGF-1 receptor inhibitors can serve as a lead for the development of anti-cancer, anti-psoriatic and anti-papilloma agents.

Original languageAmerican English
Pages (from-to)1-11
Number of pages11
JournalEuropean Journal of Pharmacology
Issue number1-2
StatePublished - 7 May 2007

Bibliographical note

Funding Information:
This study was supported by The European Commission (Prokinase Consortium) and partially by NovoTyr Therapeutics, Kiryat Shmona, Israel. We wish to thank Prof. Ben Bassat, Zippora Shlomai and Malka Chaouat for the human keratinocytes.


  • IGF-1 receptor
  • Inhibitors
  • Kinase


Dive into the research topics of 'ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents'. Together they form a unique fingerprint.

Cite this